BioTecNika - May 2015

Magzter GOLDで無制限に

読む BioTecNika 10,000以上の雑誌や新聞を1回の定期購読で購読できます

カタログを見る

1ヶ月

$14.99

1年 $149.99

$74.99

$6/month

Save 50%
Hurry, Offer Ends in 10 Days

(OR)

BioTecNikaのみを購読する

贈り物 BioTecNika

いつでもキャンセルできます。

(義務なし) ⓘ

定期購読にご満足いただけない場合は、定期購読開始日から 7 日以内に help@magzter.com までメールをお送りいただければ、全額返金いたします。質問は一切ありません。お約束します! (注: 単号購入には適用されません)

デジタルサブスクリプション

即時アクセス ⓘ

今すぐ購読すると、Magzter の Web サイト、iOS、Android、Amazon アプリですぐに読み始めることができます。

安全性を確認済み

支払い ⓘ

Magzter は Authorize.Net の認定販売業者です。詳細はこちら

この号では

The Indian biotech sector faced a major turn of events when Daiichi Sankyo, Japanese firm whose hide and seek with Indian drug company Ranbaxy came to an end as it decided to sell off its entire holding of Sun Pharmaceutical Industries and exit Indian pharma sector after a struggle of eight years. Why it had to offload Ranbaxy and what is in store with the company’s future businesses, find out in Biotecnika magazine’s May 2015 issue. Other stories to keep reader’s interest intact are “India succumbs to H1N1”, “Are we amid biotech bubble”, “Is it time to kill your R&D project?” and much more. Biotecnika bureau had a chance to interact with Ms. Anu Acharya, CEO, Mapmygenome on her entrepreneurial voyage and Dr. Anurag Mathur, Lead author, “Heart-on-chip” on his recent research. Grab your copy to find out what they had to say!

BioTecNika Description:

出版社: Biotecnika-Info-Labs-Pvt-Ltd

カテゴリ: Education

言語: English

頻度: Monthly

The essential guide to all the news in biotechnology industry & Academia run by India's Most popular Biotechnology Portal www.biotecnika.org. BioTecNika has access to world’s most influential Biotech entrepreneurs, Businesses and institutions. The magazine showcases all this via exclusive features that are insightful, informative and presented with style.

Distinguished by its indepth analysis and latest information, BioTecNika has been an indispensable part of life of Biotechies for over 8+ years. Our well-heeled readership shape opinions and trends in India and across the region. This affluent and influential group is almost impossible to reach - except through the pages of BioTecNika